Search
Mitogen-activated protein kinase kinase kinase 20
go.drugbank.com/bio_entities/BE0005595TargetHumansStress-activated component of a protein kinase signal transduction cascade that promotes programmed cell death in response to various stress, such as ribosomal stress, osmotic shock and ionizing radiation (PubMed:10924358, PubMed:1183624...
Synonyms: Human cervical cancer suppressor gene 4 proteinInsulin glargine
go.drugbank.com/drugs/DB00047ApprovedInvestigationalInsulin is typically prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic … Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
Mixtures: SOLIQUA® 10-40, SOLIQUA® 30-60Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersAntipain
go.drugbank.com/drugs/DB15251Experimental[A214484, A214487] Antipain was used in 2010 to obtain a crystal structure of the _Leishmania major_ oligopeptidase B (OPB), a serine protease that serves as a virulence factor in trypanosomatids. … [A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development
GTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. … GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: DMXB-A, 3-(2,4-dimethoxybenzylidene) anabaseineTetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalThe only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks selective potassium channels.
Categories: MATE 1 Substrates, MATE 2 SubstratesCodeine
go.drugbank.com/drugs/DB00318ApprovedIllicitInvestigationalThe relief of pain (analgesia) is a primary goal for enhancing the quality of life of patients and for increasing the ability of patients to engage in day to day activities. … [A175096] Codeine is utilized as a central analgesic, sedative, hypnotic, antinociceptive, and antiperistaltic agent, and is also recommended in certain diseases with incessant coughing.
Mixtures: Statuss Green, Fiorinal-C 1/4Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLimaprost
go.drugbank.com/drugs/DB09211InvestigationalThe drug has been sold under the trade name of Opalmon® Tablets by Ono and Prorenal® Tablets by DSP. … Limaprost alfadex has been shown to improve peripheral circulatory failure with a vasodilator action and an antithrombotic effect.
Categories: Prostaglandins EProducts: OPALMON TABLETS 5 ugGC-373
go.drugbank.com/drugs/DB15797ExperimentalGC-373 has been shown to inhibit the M<sup>pro</sup> target in various coronavirus strains, including feline, mink, and ferret M<sup>pro</sup> [A219041]. … Along with its prodrug, GC-376, GC-373 was recently investigated _in vitro_ in cell culture against SARS-Cov-2 M<sup>pro</sup> [A219036].
Categories: Heterocyclic Compounds, 1-RingCRx-401
go.drugbank.com/drugs/DB05775ExperimentalIn third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalTo date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected … Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency of factor VIII.
Products: ELOCTATE® 250 UI, ELOCTATE® 500 UI